Phase Ib/II Study of Glofitamab with Atezolizumab or Polatuzumab in B-Cell NHL
A Phase Ib/II study is assessing the safety and efficacy of Glofitamab combined with Atezolizumab or Polatuzumab in relapsed/refractory B-cell NHL.
Indication
Clinical and regulatory intelligence for B-Cell Non-Hodgkin's Lymphoma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.